CLXPF News and Press, Canadian Lynx Pete Ltd From 07/28/21

Researchers from Yale University have discovered that one dose of psilocybin administered to mice causes a quick and lasting increase in connections between neurons in the area of the brain involved in cognitive processes , known as the medial frontal cortex. Their discovery was reported ...

Digital therapeutics platform is proprietary to Cybin and the subject of the company’s 13th patent application Company focused on utilizing, leveraging cutting-edge technologies to support drug-development candidates Cybin is confident this added focus will better enable t...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, is ...

NetworkNewsWire Editorial Coverage : In July 2012, Congress created what is known as Breakthrough Therapy designation, a distinction that affords biotechnology and pharmaceutical companies an expedited review process for experimental drugs that may have treatment advantages over existing th...

A new study has found that low doses of ketamine and psilocybin can boost attention and intensify motivation associated with food in low-performing rodents. Guy Higgins, lead author of the study and CEO of InterVivo Solutions , the company that carried out the study, stated that interest ...

A study recently published in the “Journal of Psychiatric Research” discovered that childhood trauma was linked to higher symptoms of depression, particularly in individuals who demonstrated a tendency to focus on the past instead of the future or even the present. Clinical d...

Cybin (NEO: CYBN) (OTCQB: CLXPF) , a biotechnology company focused on progressing psychedelic therapeutics, will be moving exchanges. The company has announced that it  received conditional listing approval from the NYSE American LLC stock exchange. The NYSE American is designed for gr...

Cybin Inc. ( NEO:CYBN ) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has received conditional listing approval from the NYSE American LLC stock e...

Cybin (NEO: CYBN) (OTCQB: CLXPF) , a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, is sponsoring research to see if psychedelic medicine, when used with EMBARK’s supportive therapy, can help clinicians recover from COVID...

Former head of psychiatry products at FDA joins Cybin team. Laughren will help company plot its regulatory pathway as it studies and develops psychedelic medicines. Cybin (NEO: CYBN) (OTCQB: CLXPF) , a biotechnology company focused on progressing psychedelic therapeutics, is making ...